STOCK TITAN

[SC TO-T/A] Sigmatron International Inc Amended Third-Party Tender Offer

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SC TO-T/A
Rhea-AI Filing Summary

Rapid Micro Biosystems, Inc. (RPID) filed a LIVE Form 144 indicating that shareholder Robert G. Spignesi intends to sell up to 11,881 Class A shares through Fidelity Brokerage Services on or about 14 July 2025. At the disclosed aggregate market value of $39,480.56, the transaction equates to roughly 0.03 % of the company’s 39,332,172 shares outstanding, signalling minimal dilution.

The shares were acquired on 11 July 2025 via restricted-stock vesting and are therefore compensation related. The filing also details four prior sales by the same holder between 8-11 July 2025 totalling 45,562 shares for gross proceeds of about $156,780. Under Rule 144, the filer certifies that no non-public material adverse information is known.

  • Class of security: Class A common
  • Broker: Fidelity Brokerage Services LLC, Smithfield, RI
  • Proposed exchange: NASDAQ
  • Recent selling cadence: ~11–12 k shares per day during 8-11 July 2025

While the absolute dollar amount is modest, the consecutive insider sales may be monitored by investors as a sentiment indicator.

Rapid Micro Biosystems, Inc. (RPID) ha presentato un modulo LIVE 144 indicando che l'azionista Robert G. Spignesi intende vendere fino a 11.881 azioni di Classe A tramite Fidelity Brokerage Services intorno al 14 luglio 2025. Al valore di mercato complessivo dichiarato di 39.480,56 $, l'operazione corrisponde a circa il 0,03% delle 39.332.172 azioni in circolazione della società, segnalando una diluizione minima.

Le azioni sono state acquisite l'11 luglio 2025 tramite vesting di azioni vincolate e sono quindi legate a una forma di compenso. La comunicazione riporta anche quattro vendite precedenti dello stesso detentore tra l'8 e l'11 luglio 2025 per un totale di 45.562 azioni con proventi lordi di circa 156.780 $. Ai sensi della Regola 144, il dichiarante certifica che non è a conoscenza di informazioni materiali riservate negative.

  • Categoria di titolo: azioni ordinarie di Classe A
  • Broker: Fidelity Brokerage Services LLC, Smithfield, RI
  • Borsa proposta: NASDAQ
  • Frequenza recente di vendita: circa 11–12 mila azioni al giorno dall'8 all'11 luglio 2025

Pur essendo l'importo assoluto modesto, le vendite consecutive da parte di un insider potrebbero essere monitorate dagli investitori come indicatore di sentiment.

Rapid Micro Biosystems, Inc. (RPID) presentó un Formulario LIVE 144 indicando que el accionista Robert G. Spignesi planea vender hasta 11,881 acciones Clase A a través de Fidelity Brokerage Services alrededor del 14 de julio de 2025. Con un valor de mercado agregado divulgado de $39,480.56, la transacción equivale aproximadamente al 0.03% de las 39,332,172 acciones en circulación de la compañía, indicando una dilución mínima.

Las acciones fueron adquiridas el 11 de julio de 2025 mediante la consolidación de acciones restringidas y por lo tanto están relacionadas con compensación. La presentación también detalla cuatro ventas previas por parte del mismo titular entre el 8 y el 11 de julio de 2025, totalizando 45,562 acciones con ingresos brutos de aproximadamente $156,780. Bajo la Regla 144, el declarante certifica que no conoce información material confidencial adversa.

  • Clase de valor: acciones comunes Clase A
  • Corredor: Fidelity Brokerage Services LLC, Smithfield, RI
  • Bolsa propuesta: NASDAQ
  • Ritmo reciente de ventas: ~11–12 mil acciones por día durante el 8-11 de julio de 2025

Aunque el monto absoluto es modesto, las ventas consecutivas de un insider podrían ser observadas por inversores como un indicador de sentimiento.

Rapid Micro Biosystems, Inc. (RPID)는 LIVE Form 144를 제출하여 주주 Robert G. Spignesi가 약 2025년 7월 14일경 Fidelity Brokerage Services를 통해 최대 11,881주 Class A 주식을 매도할 예정임을 알렸습니다. 공개된 총 시장 가치는 $39,480.56로, 이는 회사의 39,332,172주 발행 주식의 약 0.03%에 해당하여 희석 효과가 미미함을 나타냅니다.

해당 주식은 2025년 7월 11일 제한 주식 권리 확정(vesting)을 통해 취득되었으며, 따라서 보상과 관련된 주식입니다. 제출 서류에는 같은 보유자가 2025년 7월 8일부터 11일 사이에 총 45,562주를 매도하여 약 $156,780의 총 수익을 올린 네 차례의 이전 매도 내역도 상세히 기재되어 있습니다. Rule 144에 따라 제출자는 비공개 중대한 부정적 정보가 없음을 인증합니다.

  • 증권 종류: Class A 보통주
  • 중개인: Fidelity Brokerage Services LLC, Smithfield, RI
  • 예정 거래소: NASDAQ
  • 최근 매도 빈도: 2025년 7월 8일부터 11일까지 하루 약 11,000~12,000주

총 금액은 크지 않지만, 연속적인 내부자 매도는 투자자들에게 심리 지표로 주목될 수 있습니다.

Rapid Micro Biosystems, Inc. (RPID) a déposé un formulaire LIVE 144 indiquant que l'actionnaire Robert G. Spignesi prévoit de vendre jusqu'à 11 881 actions de Classe A via Fidelity Brokerage Services aux alentours du 14 juillet 2025. À la valeur marchande agrégée divulguée de 39 480,56 $, la transaction représente environ 0,03 % des 39 332 172 actions en circulation de la société, signalant une dilution minimale.

Les actions ont été acquises le 11 juillet 2025 par acquisition progressive de stock restreint et sont donc liées à une rémunération. Le dépôt détaille également quatre ventes antérieures par le même détenteur entre le 8 et le 11 juillet 2025 totalisant 45 562 actions pour un produit brut d'environ 156 780 $. En vertu de la règle 144, le déclarant certifie qu'il n'a pas connaissance d'informations défavorables importantes non publiques.

  • Catégorie de titre : actions ordinaires de Classe A
  • Intermédiaire : Fidelity Brokerage Services LLC, Smithfield, RI
  • Bourse proposée : NASDAQ
  • Rythme récent de vente : environ 11–12 000 actions par jour du 8 au 11 juillet 2025

Bien que le montant absolu soit modeste, les ventes consécutives d'initiés pourraient être surveillées par les investisseurs comme un indicateur de sentiment.

Rapid Micro Biosystems, Inc. (RPID) hat ein LIVE Formular 144 eingereicht, das angibt, dass der Aktionär Robert G. Spignesi beabsichtigt, bis zu 11.881 Class A Aktien über Fidelity Brokerage Services etwa am 14. Juli 2025 zu verkaufen. Bei einem angegebenen Gesamtmarktwert von 39.480,56 $ entspricht die Transaktion etwa 0,03 % der 39.332.172 ausstehenden Aktien des Unternehmens, was auf eine minimale Verwässerung hinweist.

Die Aktien wurden am 11. Juli 2025 durch Restricted-Stock-Vesting erworben und sind somit vergütungsbezogen. Die Meldung enthält außerdem vier frühere Verkäufe desselben Inhabers zwischen dem 8. und 11. Juli 2025 mit insgesamt 45.562 Aktien und Bruttoerlösen von etwa 156.780 $. Nach Regel 144 bestätigt der Melder, dass keine nicht-öffentlichen wesentlichen nachteiligen Informationen bekannt sind.

  • Wertpapierklasse: Class A Stammaktien
  • Broker: Fidelity Brokerage Services LLC, Smithfield, RI
  • Vorgeschlagene Börse: NASDAQ
  • Jüngste Verkaufsfrequenz: ca. 11–12 Tausend Aktien pro Tag vom 8. bis 11. Juli 2025

Obwohl der absolute Geldbetrag gering ist, könnten aufeinanderfolgende Insider-Verkäufe von Investoren als Stimmungsindikator beobachtet werden.

Positive
  • Transparent disclosure via timely Form 144 allows investors to track insider activity.
  • Dilution impact is negligible: 11,881 shares equal ~0.03 % of total shares outstanding.
Negative
  • Continued insider selling (over 57 k shares within one week) may be interpreted as weak insider conviction.
  • Additional market supply of shares could exert minor short-term pressure on RPID’s share price.

Insights

TL;DR: Small, routine insider sale; negligible dilution, modest negative sentiment.

The Form 144 registers another 11,881 RPID shares for sale by Robert G. Spignesi, following four sales over the preceding week. Collectively (~57 k shares) the disposals represent only 0.15 % of outstanding shares and stem from RSU vesting, suggesting liquidity management rather than a strategic exit. The dollar value is immaterial and should not affect fundamentals, but continuing insider supply can weigh marginally on market perception until absorbed.

Rapid Micro Biosystems, Inc. (RPID) ha presentato un modulo LIVE 144 indicando che l'azionista Robert G. Spignesi intende vendere fino a 11.881 azioni di Classe A tramite Fidelity Brokerage Services intorno al 14 luglio 2025. Al valore di mercato complessivo dichiarato di 39.480,56 $, l'operazione corrisponde a circa il 0,03% delle 39.332.172 azioni in circolazione della società, segnalando una diluizione minima.

Le azioni sono state acquisite l'11 luglio 2025 tramite vesting di azioni vincolate e sono quindi legate a una forma di compenso. La comunicazione riporta anche quattro vendite precedenti dello stesso detentore tra l'8 e l'11 luglio 2025 per un totale di 45.562 azioni con proventi lordi di circa 156.780 $. Ai sensi della Regola 144, il dichiarante certifica che non è a conoscenza di informazioni materiali riservate negative.

  • Categoria di titolo: azioni ordinarie di Classe A
  • Broker: Fidelity Brokerage Services LLC, Smithfield, RI
  • Borsa proposta: NASDAQ
  • Frequenza recente di vendita: circa 11–12 mila azioni al giorno dall'8 all'11 luglio 2025

Pur essendo l'importo assoluto modesto, le vendite consecutive da parte di un insider potrebbero essere monitorate dagli investitori come indicatore di sentiment.

Rapid Micro Biosystems, Inc. (RPID) presentó un Formulario LIVE 144 indicando que el accionista Robert G. Spignesi planea vender hasta 11,881 acciones Clase A a través de Fidelity Brokerage Services alrededor del 14 de julio de 2025. Con un valor de mercado agregado divulgado de $39,480.56, la transacción equivale aproximadamente al 0.03% de las 39,332,172 acciones en circulación de la compañía, indicando una dilución mínima.

Las acciones fueron adquiridas el 11 de julio de 2025 mediante la consolidación de acciones restringidas y por lo tanto están relacionadas con compensación. La presentación también detalla cuatro ventas previas por parte del mismo titular entre el 8 y el 11 de julio de 2025, totalizando 45,562 acciones con ingresos brutos de aproximadamente $156,780. Bajo la Regla 144, el declarante certifica que no conoce información material confidencial adversa.

  • Clase de valor: acciones comunes Clase A
  • Corredor: Fidelity Brokerage Services LLC, Smithfield, RI
  • Bolsa propuesta: NASDAQ
  • Ritmo reciente de ventas: ~11–12 mil acciones por día durante el 8-11 de julio de 2025

Aunque el monto absoluto es modesto, las ventas consecutivas de un insider podrían ser observadas por inversores como un indicador de sentimiento.

Rapid Micro Biosystems, Inc. (RPID)는 LIVE Form 144를 제출하여 주주 Robert G. Spignesi가 약 2025년 7월 14일경 Fidelity Brokerage Services를 통해 최대 11,881주 Class A 주식을 매도할 예정임을 알렸습니다. 공개된 총 시장 가치는 $39,480.56로, 이는 회사의 39,332,172주 발행 주식의 약 0.03%에 해당하여 희석 효과가 미미함을 나타냅니다.

해당 주식은 2025년 7월 11일 제한 주식 권리 확정(vesting)을 통해 취득되었으며, 따라서 보상과 관련된 주식입니다. 제출 서류에는 같은 보유자가 2025년 7월 8일부터 11일 사이에 총 45,562주를 매도하여 약 $156,780의 총 수익을 올린 네 차례의 이전 매도 내역도 상세히 기재되어 있습니다. Rule 144에 따라 제출자는 비공개 중대한 부정적 정보가 없음을 인증합니다.

  • 증권 종류: Class A 보통주
  • 중개인: Fidelity Brokerage Services LLC, Smithfield, RI
  • 예정 거래소: NASDAQ
  • 최근 매도 빈도: 2025년 7월 8일부터 11일까지 하루 약 11,000~12,000주

총 금액은 크지 않지만, 연속적인 내부자 매도는 투자자들에게 심리 지표로 주목될 수 있습니다.

Rapid Micro Biosystems, Inc. (RPID) a déposé un formulaire LIVE 144 indiquant que l'actionnaire Robert G. Spignesi prévoit de vendre jusqu'à 11 881 actions de Classe A via Fidelity Brokerage Services aux alentours du 14 juillet 2025. À la valeur marchande agrégée divulguée de 39 480,56 $, la transaction représente environ 0,03 % des 39 332 172 actions en circulation de la société, signalant une dilution minimale.

Les actions ont été acquises le 11 juillet 2025 par acquisition progressive de stock restreint et sont donc liées à une rémunération. Le dépôt détaille également quatre ventes antérieures par le même détenteur entre le 8 et le 11 juillet 2025 totalisant 45 562 actions pour un produit brut d'environ 156 780 $. En vertu de la règle 144, le déclarant certifie qu'il n'a pas connaissance d'informations défavorables importantes non publiques.

  • Catégorie de titre : actions ordinaires de Classe A
  • Intermédiaire : Fidelity Brokerage Services LLC, Smithfield, RI
  • Bourse proposée : NASDAQ
  • Rythme récent de vente : environ 11–12 000 actions par jour du 8 au 11 juillet 2025

Bien que le montant absolu soit modeste, les ventes consécutives d'initiés pourraient être surveillées par les investisseurs comme un indicateur de sentiment.

Rapid Micro Biosystems, Inc. (RPID) hat ein LIVE Formular 144 eingereicht, das angibt, dass der Aktionär Robert G. Spignesi beabsichtigt, bis zu 11.881 Class A Aktien über Fidelity Brokerage Services etwa am 14. Juli 2025 zu verkaufen. Bei einem angegebenen Gesamtmarktwert von 39.480,56 $ entspricht die Transaktion etwa 0,03 % der 39.332.172 ausstehenden Aktien des Unternehmens, was auf eine minimale Verwässerung hinweist.

Die Aktien wurden am 11. Juli 2025 durch Restricted-Stock-Vesting erworben und sind somit vergütungsbezogen. Die Meldung enthält außerdem vier frühere Verkäufe desselben Inhabers zwischen dem 8. und 11. Juli 2025 mit insgesamt 45.562 Aktien und Bruttoerlösen von etwa 156.780 $. Nach Regel 144 bestätigt der Melder, dass keine nicht-öffentlichen wesentlichen nachteiligen Informationen bekannt sind.

  • Wertpapierklasse: Class A Stammaktien
  • Broker: Fidelity Brokerage Services LLC, Smithfield, RI
  • Vorgeschlagene Börse: NASDAQ
  • Jüngste Verkaufsfrequenz: ca. 11–12 Tausend Aktien pro Tag vom 8. bis 11. Juli 2025

Obwohl der absolute Geldbetrag gering ist, könnten aufeinanderfolgende Insider-Verkäufe von Investoren als Stimmungsindikator beobachtet werden.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 
SCHEDULE TO/A
 
TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)


 
SIGMATRON INTERNATIONAL, INC.
(Name of Subject Company (Issuer))
 
TRANSOM AXIS MERGERSUB, INC.
(Names of Filing Persons (Offeror))
a direct wholly owned subsidiary of
 
TRANSOM AXIS ACQUIRECO, LLC
(Names of Filing Persons (Parent of Offeror))
a direct wholly owned subsidiary of

TRANSOM AXIS HOLDCO, INC.
TRANSOM AXIS TOPCO, LLC
TRANSOM CAPITAL FUND IV, L.P.
(Names of Filing Persons (Other Persons))

Common Stock, par value $0.01 per share
(Title of Class of Securities)

82661L 101
(CUSIP Number of Class of Securities (Underlying Common Stock))

Russell Roenick
Transom Capital Group, LLC
100 N. Pacific Coast Highway, Suite 1725
El Segundo, California 90245
Telephone: +1 (310) 407-0940
 
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)


Copies to:

Robert E. Goedert, P.C.
Kevin M. Frank
Kirkland & Ellis LLP
333 West Wolf Point Plaza
Chicago, Illinois 60654
(312) 862-2000


Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
 
Check the appropriate boxes below to designate any transactions to which the statement relates:

 
Third-party tender offer subject to Rule 14d-1.
 
Issuer tender offer subject to Rule 13e-4.
 
Going-private transaction subject to Rule 13e-3.
 
Amendment to Schedule 13D under Rule 13d-2.
 
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
 
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
 
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)



This Amendment No. 1 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 26, 2025, (as amended and together with any subsequent amendments and supplements hereto, the “Schedule TO”), by Transom Axis MergerSub, Inc., (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of Transom Axis AcquireCo, LLC a Delaware limited liability company (“Parent”).

The Schedule TO relates to the tender offer by Merger Sub to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of SigmaTron International, Inc., a Delaware corporation (the “Company”), in exchange for (i) $3.02 per Share (the “Offer Price”), net to the stockholder in cash, without interest and less any required tax withholding, upon the terms and subject to the conditions set forth in this Letter of Transmittal and in the related Offer to Purchase, dated June 26, 2025 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (as it may be amended or supplemented from time to time, the “Letter of Transmittal”), copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
 
Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged. This Amendment is being filed to reflect certain updates as reflected below. Capitalized terms used but not defined herein have the meanings assigned to such terms in the Offer to Purchase or the Schedule TO. You should read this Amendment together with the Schedule TO and the Offer to Purchase.

Items 1 through 9 and Item 11.
 
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items 1 through 9 and Item 11 incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:
 
Section 16 (Certain Legal Matters; Regulatory Approvals) of the Offer to Purchase is amended by adding the following new sub-heading and paragraphs immediately following the end of the last paragraph of such section:
 
Legal Proceedings Relating to the Tender Offer
 
On June 26, 2025, SigmaTron and the members of the SigmaTron Board were named as defendants in a complaint captioned David Elliott v. SigmaTron International, Inc. et al., Index No. 653878/2025, filed in the Supreme Court of the State of New York, County of New York (the ‘‘Elliot Complaint’’). On June 27, 2025, SigmaTron and the members of the SigmaTron Board were named as defendants in a complaint captioned Robert Williams v. SigmaTron International, Inc. et al., Index No. 653885/2025, filed in the Supreme Court of the State of New York, County of New York (the ‘‘Williams Complaint’’). Each of the Elliot Complaint and the Williams Complaint alleges, among other things, that the Schedule 14D-9 omits or misrepresents material information in violation of New York common law. Each of the Elliot Complaint and Williams Complaint seeks, among other things, an injunction of the Transactions until the defendants make additional disclosures. SigmaTron believes that the Elliot Complaint and the Williams Complaint are each without merit.
 
In addition, as of July 11, 2025, SigmaTron has received several demand letters from purported SigmaTron stockholders generally alleging deficiencies in the disclosures associated with the Transactions. SigmaTron believes that these demand letters are without merit.
 
It is possible that additional demand letters or complaints may be received by or filed against SigmaTron, the SigmaTron Board, Parent or Merger Sub. If such additional demand letters are received or complaints are filed, absent new or different allegations that are material, SigmaTron, Parent and Merger Sub will not necessarily disclose them. The outcome of the matters described above cannot be predicted with certainty.

2

SIGNATURES
 
After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
 
Date: July 14, 2025
TRANSOM AXIS MERGERSUB, INC.
   
 
/s/ Russell Roenick
 
Name:
Russell Roenick
 
Title:
President
   
 
TRANSOM AXIS ACQUIRECO, LLC
   
 
/s/ Russell Roenick
 
Name:
Russell Roenick
 
Title:
President
   
 
TRANSOM AXIS HOLDCO, INC.
   
 
/s/ Russell Roenick
 
Name:
Russell Roenick
 
Title:
President
   
 
TRANSOM AXIS TOPCO, LLC
   
 
/s/ Russell Roenick
 
Name:
Russell Roenick
 
Title:
President
   
 
TRANSOM CAPITAL FUND IV, L.P.
   
 
/s/ Russell Roenick
 
Name:
Russell Roenick
 
Title:
Authorized Signatory


3

Sigmatron Intl

NASDAQ:SGMA

SGMA Rankings

SGMA Latest News

SGMA Latest SEC Filings

SGMA Stock Data

18.36M
4.94M
19.33%
18.53%
0.28%
Electronic Components
Printed Circuit Boards
Link
United States
ELK GROVE VILLAGE